Analysts at both Stifel and Jefferies have estimated a 4-5p increase in Arix Bioscience’s (ARIX) net asset value, up to around 159/160p.
The Stifel note explained the drive in Arix’s value was likely a knock-on effect from troubled fund manager Neil Woodford selling his stake in Autolus. Arix holds a 7.6% interest in Autolus, which suffered serious overhang following the suspension of Woodford Equity Income (WEI).
WEI held nearly a quarter of Autolus' shares and the stake made up 16% of the WEI fund's net asset value.
Arix’s share price jumped after Woodford's sell off, rising nearly 8% to 116p.
The Stifel note also emphasised how key upcoming milestones for Arix coupled with the reduction of overhang risk is likely to continue driving up it valuation.
For more news and updates on Arix Bioscience